What You Need To Know About Mosquirix, The New Malaria Vaccine #shorts
4Mosquirix is the first approved malaria vaccine in the world, and it could save millions of lives from this deadly disease. But how does it work, and what are the challenges and opportunities of its implementation? In this video description, I will explain the science, history, and future of Mosquirix.
Malaria is a serious problem that affects millions of people every year, especially in Africa. It is caused by a parasite that is transmitted by mosquitoes. Malaria can cause fever, headache, vomiting, and even death if not treated.
Mosquirix is a recombinant protein-based malaria vaccine that helps protect children aged 6 weeks to 17 months against malaria caused by the parasite Plasmodium falciparum and against hepatitis B. It was developed by GlaxoSmithKline and the Walter Reed Army Institute of Research, and has been funded by the PATH Malaria Vaccine Initiative and the Bill and Melinda Gates Foundation.
Mosquirix works by stimulating the immune system to produce antibodies that can fight the malaria parasite. However, it is not 100% effective, and it requires four doses to be administered over 18 months. It also needs to be stored and transported at low temperatures, which can be challenging in remote areas.
Mosquirix is a breakthrough for global health, as it is the first vaccine to show some protection against malaria in children, who are the most vulnerable to the disease. It could prevent millions of deaths and reduce the burden of malaria on health systems and economies. However, it is not a silver bullet, and it needs to be used along with other measures, such as bed nets, insecticides, and antimalarial drugs.
If you enjoyed this video, please give it a thumbs up and share it with your friends. And don't forget to subscribe to my channel and hit the bell icon to get notified when I upload new videos.
Thank you for watching. π